RESPONDING to interest from pharmaceutical companies and cancer patient advocacy groups, the Minister for Health Greg Hunt has requested that the Pharmaceutical Benefits Advisory Committee (PBAC) consider options for listing of pan-tumour indications for PDL1 cancer immunotherapies on the Pharmaceutical Benefits Scheme (PBS).
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 21 Feb 18
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Feb 18
